GLPwatch

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

NCT06852391 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how the body’s metabolism changes after weight loss in teenagers with obesity who participate in a lifestyle program, with or without the medication semaglutide.

Status Recruiting Currently enrolling participants.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 74 people Planned (estimated).
Who can join Ages 12–17 · all sexes
Timeline Started 2025-06 · est. completion 2027-12
Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06852391 ↗

Description as written by the study sponsor.

The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity. Behavioural lifestyle intervention with and without a pharmacological intervention - semaglutide- will be studied. Study participants will be randomized to one of two groups. Group A will follow a behavioral lifestyle program (BLP) alone for 6 months, followed by BLP and treatment with semaglutide for six months. Group B will be enrolled in BLP and semaglutide from baseline to 6 months. The primary research question will assess, in youth aged 12-17 years diagnosed with obesity and enrolled in a weight management program, if the implementation of a BLP together with semaglutide, compared to the implementation of BLP alone for 6 months leads to less adaptive thermogenesis.

Treatments tested

Main thing measuredMeasurement of Adaptive thermogenesis
SponsorMcMaster University
Conditions studiedObesity (Disorder)
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06852391 ↗